Table 1 Mean expression of target gene to endogenous control (GAPDH and ACTB) ± SD, relative to control.

From: A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation

Target

Control

Dry eye

UAMC-00050

Vehicle

Palpebral + bulbar conjunctiva

IL-1α

1.00 ± 0.29

1.50 ± 0.49*

0.95 ± 0.43

0.96 ± 0.24

IL-17A

1.00 ± 1.38

4.12 ± 2.20**

0.21 ± 1.50

0.50 ± 1.70

Tryptase

1.00 ± 0.55

1.62 ± 0.44*

1.61 ± 0.64

1.66 ± 0.52*

Matriptase

1.00 ± 0.10

0.98 ± 0.15

1.01 ± 0.21

1.11 ± 0.29

PAR2

1.00 ± 0.06

1.18 ± 0.39

1.10 ± 0.20

1.05 ± 0.26

uPAR

1.00 ± 0.35

1.40 ± 0.32*

1.80 ± 0.16**

2.83 ± 0.25**

Cornea

Tryptase

1.00 ± 0.50

1.59 ± 0.52*

1.58 ± 0.75

2.68 ± 1.01**

Matriptase

1.00 ± 0.19

1.15 ± 0.16

0.89 ± 0.25

0.91 ± 0.23

PAR2

1.00 ± 0.27

1.28 ± 0.19*

1.22 ± 0.21

1.23 ± 0.15

uPAR

1.00 ± 0.47

1.22 ± 0.52

1.65 ± 0.40*

1.47 ± 0.45

  1. N = 8, comparative qRT-PCR.
  2. *p < 0.05, **p < 0.01 versus control.